CA3037469C - Treatment of dermal disorders comprising a mtorc1 inhibitor - Google Patents
Treatment of dermal disorders comprising a mtorc1 inhibitor Download PDFInfo
- Publication number
- CA3037469C CA3037469C CA3037469A CA3037469A CA3037469C CA 3037469 C CA3037469 C CA 3037469C CA 3037469 A CA3037469 A CA 3037469A CA 3037469 A CA3037469 A CA 3037469A CA 3037469 C CA3037469 C CA 3037469C
- Authority
- CA
- Canada
- Prior art keywords
- dermal
- composition
- rapamycin
- salt
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232228P | 2015-09-24 | 2015-09-24 | |
| US62/232,228 | 2015-09-24 | ||
| PCT/US2016/052442 WO2017053222A1 (en) | 2015-09-24 | 2016-09-19 | Novel compositions and methods for treating or preventing dermal disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3037469A1 CA3037469A1 (en) | 2017-03-30 |
| CA3037469C true CA3037469C (en) | 2024-04-16 |
Family
ID=58387119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037469A Active CA3037469C (en) | 2015-09-24 | 2016-09-19 | Treatment of dermal disorders comprising a mtorc1 inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10695326B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3352755B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2018528236A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180081501A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108348508A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016325446B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3037469C (cg-RX-API-DMAC7.html) |
| ES (1) | ES3060762T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017053222A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
| WO2017053222A1 (en) * | 2015-09-24 | 2017-03-30 | Drexel University | Novel compositions and methods for treating or preventing dermal disorders |
| US20190167649A1 (en) * | 2016-08-10 | 2019-06-06 | The Board Of Regents Of The University Of Texas System | Topical rapamycin therapy |
| WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| EP3863606A4 (en) * | 2018-10-11 | 2022-07-20 | Drexel University | METHODS OF TREATMENT OR PREVENTION OF SKIN DISEASES |
| JP7516252B2 (ja) * | 2018-11-02 | 2024-07-16 | 株式会社 資生堂 | オルタナティブオートファジー誘導剤を含む紫外線起因性炎症抑制剤 |
| KR102132921B1 (ko) * | 2018-12-13 | 2020-07-13 | 영남대학교 산학협력단 | 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물 |
| AU2020277132B1 (en) | 2020-11-24 | 2021-11-04 | Aft Pharmaceuticals Limited | A Rapamycin Composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| GB9723669D0 (en) | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
| US20040180430A1 (en) | 1999-09-07 | 2004-09-16 | West Michael D. | Methods of restoring telomere length and extending cell lifespan using nuclear transfer |
| US7026374B2 (en) | 2002-06-25 | 2006-04-11 | Aruna Nathan | Injectable microdispersions for medical applications |
| EP1646635A1 (en) | 2003-07-16 | 2006-04-19 | Wyeth | Cci-779 isomer c |
| US20050250805A1 (en) * | 2004-05-06 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Pharmaceutical ointment formulations |
| KR20070121746A (ko) | 2005-03-14 | 2007-12-27 | 매크로켐 코포레이션 | 사람 피부를 통한 마크롤라이드 침투의 개선 |
| AU2007230964B2 (en) | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| MXPA06008797A (es) * | 2006-08-03 | 2008-02-04 | Fernando Ahumada Ayala | Preparacion topica para el tratamiento de enfermedades inflamatorias de la piel que contiene sirolimus. |
| WO2008022256A2 (en) * | 2006-08-16 | 2008-02-21 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| EP2155146A4 (en) | 2007-05-15 | 2012-11-21 | Puretech Ventures | METHOD AND COMPOSITIONS FOR TREATING SKIN TREATMENTS |
| WO2009046436A1 (en) * | 2007-10-04 | 2009-04-09 | Memorial Sloan-Kettering Cancer Center | Methods for inhibiting senescence of epithelial cells |
| WO2010056778A1 (en) * | 2008-11-11 | 2010-05-20 | Signum Biosciences, Inc. | Isoprenyl compounds and methods thereof |
| AU2013204219B2 (en) * | 2009-04-10 | 2015-05-07 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| WO2010118419A2 (en) * | 2009-04-10 | 2010-10-14 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| US20110150856A1 (en) | 2009-12-21 | 2011-06-23 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
| WO2011079154A1 (en) * | 2009-12-21 | 2011-06-30 | Sarah Bacus | Compositions and methods for treatment of vitiligo |
| JP5652795B2 (ja) * | 2011-01-31 | 2015-01-14 | 国立大学法人大阪大学 | 皮膚疾患を処置するための外用薬およびその製造方法 |
| WO2012142145A1 (en) | 2011-04-12 | 2012-10-18 | Dow Pharmaceutical Sciences | Methods of treating skin conditions exhibiting telangiectasia |
| CN104080786A (zh) * | 2011-11-08 | 2014-10-01 | 因特利凯有限责任公司 | 使用多种药剂的治疗方案 |
| WO2014004692A1 (en) | 2012-06-26 | 2014-01-03 | Sarah Bacus | Compositions and methods for treatment vitiligo |
| US9296733B2 (en) * | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| EA201690987A1 (ru) * | 2013-11-13 | 2016-10-31 | Новартис Аг | Низкодозовые иммуностимулирующие ингибиторы mtor и их применения |
| US9980976B2 (en) * | 2015-02-17 | 2018-05-29 | Northwestern University | Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists |
| WO2017053222A1 (en) | 2015-09-24 | 2017-03-30 | Drexel University | Novel compositions and methods for treating or preventing dermal disorders |
-
2016
- 2016-09-19 WO PCT/US2016/052442 patent/WO2017053222A1/en not_active Ceased
- 2016-09-19 CN CN201680065172.4A patent/CN108348508A/zh active Pending
- 2016-09-19 ES ES16849389T patent/ES3060762T3/es active Active
- 2016-09-19 CN CN202211246255.7A patent/CN115645534A/zh active Pending
- 2016-09-19 KR KR1020187011292A patent/KR20180081501A/ko not_active Ceased
- 2016-09-19 EP EP16849389.8A patent/EP3352755B1/en active Active
- 2016-09-19 EP EP25225780.3A patent/EP4729121A3/en active Pending
- 2016-09-19 JP JP2018515561A patent/JP2018528236A/ja not_active Withdrawn
- 2016-09-19 AU AU2016325446A patent/AU2016325446B2/en active Active
- 2016-09-19 CA CA3037469A patent/CA3037469C/en active Active
- 2016-09-19 US US15/762,317 patent/US10695326B2/en active Active
-
2020
- 2020-05-21 US US16/880,186 patent/US11179374B2/en active Active
-
2021
- 2021-08-11 US US17/399,763 patent/US20220031673A1/en active Pending
- 2021-10-15 JP JP2021169263A patent/JP7332666B2/ja active Active
-
2023
- 2023-08-10 JP JP2023130574A patent/JP7573078B2/ja active Active
-
2026
- 2026-03-30 US US19/633,526 patent/US20260224540A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016325446B2 (en) | 2021-05-13 |
| US20200281903A1 (en) | 2020-09-10 |
| JP7573078B2 (ja) | 2024-10-24 |
| US20180280362A1 (en) | 2018-10-04 |
| JP7332666B2 (ja) | 2023-08-23 |
| JP2018528236A (ja) | 2018-09-27 |
| EP3352755B1 (en) | 2025-12-24 |
| US10695326B2 (en) | 2020-06-30 |
| CN108348508A (zh) | 2018-07-31 |
| KR20180081501A (ko) | 2018-07-16 |
| US11179374B2 (en) | 2021-11-23 |
| CN115645534A (zh) | 2023-01-31 |
| CA3037469A1 (en) | 2017-03-30 |
| US20260224540A1 (en) | 2026-08-06 |
| JP2022009168A (ja) | 2022-01-14 |
| AU2016325446A1 (en) | 2018-04-19 |
| WO2017053222A1 (en) | 2017-03-30 |
| EP3352755A1 (en) | 2018-08-01 |
| ES3060762T3 (en) | 2026-03-30 |
| EP4729121A3 (en) | 2026-06-24 |
| EP3352755A4 (en) | 2019-04-03 |
| HK1258696A1 (en) | 2019-11-15 |
| EP4729121A2 (en) | 2026-04-22 |
| US20220031673A1 (en) | 2022-02-03 |
| JP2023154020A (ja) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11179374B2 (en) | Compositions and methods for treating or preventing dermal disorders | |
| US20240108645A1 (en) | Senescence and senescence associated secretory phenotype | |
| Lamming et al. | Rapalogs and mTOR inhibitors as anti-aging therapeutics | |
| Vin et al. | BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling | |
| US9555034B2 (en) | Compositions and methods for treating skin cancer associated diseases | |
| CN101155577B (zh) | 神经纤维瘤的局部治疗 | |
| AU2010250814B2 (en) | Mitochondrial activity inhibitors of cancer-initiating cells and use thereof | |
| TW201244716A (en) | Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor | |
| Maia et al. | Mitotherapy prevents peripheral neuropathy induced by oxaliplatin in mice | |
| US9629851B2 (en) | ROCK in combination with MAPK pathway | |
| KR20120133389A (ko) | 만성 활성 b-세포-수용체 신호전달이 있는 b-세포 림프종의 치료를 위한 pkc 억제제 | |
| HK1258696B (en) | Topical composition comprising rapamycin for use in treating or preventing seborrheic keratosis or actinic keratosis | |
| US20220211702A1 (en) | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | |
| WO2013059548A9 (en) | Compositions and methods for treating cancer using jak2 inhibitor | |
| Zhao et al. | Increased phosphodiesterase 3A/4B expression after angioplasty and the effect on VASP phosphorylation | |
| US11759434B2 (en) | Methods and compositions for treating melanoma and non-melanoma skin cancers | |
| Keser et al. | Comparative Analysis of CDK4/6 Inhibitors (Ribociclib and Palbociclib) combined with Enzalutamide in Triple-negative breast cancer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210913 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240911 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240911 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240911 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250909 |